RESMED INC — Director's Dealing 2025

Mar 4, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RESMED INC (RMD)
CIK: 0000943819
Period of Report: 2025-03-03

Reporting Person: Ghoshal Kaushik (Chief Commercial Officer, SaaS)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-03	ResMed Common Stock	M	367	$211.76	Acquired	10092	Direct
2025-03-03	ResMed Common Stock	M	3506	$146.34	Acquired	13598	Direct
2025-03-03	ResMed Common Stock	M	514	$146.34	Acquired	14112	Direct
2025-03-03	ResMed Common Stock	M	4726	$211.76	Acquired	18838	Direct
2025-03-03	ResMed Common Stock	S	367	$235.2486	Disposed	18471	Direct
2025-03-03	ResMed Common Stock	S	3506	$235.3988	Disposed	14965	Direct
2025-03-03	ResMed Common Stock	S	514	$235.2486	Disposed	14451	Direct
2025-03-03	ResMed Common Stock	S	4726	$235.4261	Disposed	9725	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-03-03	ResMed Common Stock Options	$211.76	M	367	Disposed	2027-11-19	ResMed Common Stock (367)	Direct
2025-03-03	ResMed Common Stock Options	$146.34	M	3506	Disposed	2026-11-21	ResMed Common Stock (3506)	Direct
2025-03-03	ResMed Common Stock Options	$146.34	M	514	Disposed	2026-11-21	ResMed Common Stock (514)	Direct
2025-03-03	ResMed Common Stock Options	$211.76	M	4726	Disposed	2027-11-19	ResMed Common Stock (4726)	Direct

Footnotes

F1: The transaction was conducted under a Rule 10b5-1 plan adopted November 29, 2024.

F2: This transaction was executed in multiple trades at prices ranging from $235.00 - $236.18. The price reported above reflects the weighted average sale price.

F3: Represents date options first become exercisable. Options vest 1/3 per year.